<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578354</url>
  </required_header>
  <id_info>
    <org_study_id>Pending</org_study_id>
    <nct_id>NCT03578354</nct_id>
  </id_info>
  <brief_title>4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine</brief_title>
  <official_title>Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or
      atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular
      migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on
      study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding not acquired
  </why_stopped>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Dizziness Handicap Score</measure>
    <time_frame>14 weeks</time_frame>
    <description>Dizziness Handicap Inventory (DHI) will be compared pre- and post- study drug treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of dizziness episodes</measure>
    <time_frame>14 weeks</time_frame>
    <description>Incidence of dizziness episodes will be compared pre- and post- study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motion sickness susceptibility</measure>
    <time_frame>14 weeks</time_frame>
    <description>Motion sickness susceptibility questionnaire (MSSQ) will be compared pre- and post- study drug treatment. MSSQ is reported as a scale (0 - 100) with 0 being no or very little experience of motion sickness, and 100 being very frequent experience of motion sickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in roll tilt perceptual threshold</measure>
    <time_frame>14 weeks</time_frame>
    <description>Rolt tilt perceptual thresholds will be compared pre- and post- study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vestibulo-ocular reflex (VOR) time constant</measure>
    <time_frame>14 weeks</time_frame>
    <description>Standard low-frequency rotational testing to measure VOR will be compared pre- and post- study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of migraine episodes</measure>
    <time_frame>14 weeks</time_frame>
    <description>Incidence of migraine episodes will be compared pre- and post- study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Headache Impact Test (HIT) score</measure>
    <time_frame>14 weeks</time_frame>
    <description>Headache Impact Test (HIT) will be compared pre- and post- study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life score</measure>
    <time_frame>14 weeks</time_frame>
    <description>Quality of life will be measured using 36-Item Short Form Health Survey (SF-36) questionnaires and compared pre- and post- study drug treatment. The SF-36 consists of 8 sub-scores. Each score is reported as a scale (0 - 100) with 0 being maximally disabled and 100 having no disability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vestibular Migraine</condition>
  <condition>Migraine Disorders</condition>
  <condition>Vestibular Diseases</condition>
  <arm_group>
    <arm_group_label>4-AP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg 4-aminopyridine twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg atenolol twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Masked placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4-aminopyridine</intervention_name>
    <description>an oral drug to be swallowed</description>
    <arm_group_label>4-AP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>an oral drug to be swallowed</description>
    <arm_group_label>Atenolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a masked placebo to be swallowed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe vestibular migraine (VM)

        Exclusion Criteria:

          -  Neurologic or otologic disease other than VM

          -  Psychiatric illness requiring medication

          -  Medical illness including cancer, coronary artery or cerebrovascular disease

          -  Known allergy to one of the test medications

          -  Contraindication to use of one of the test medications - asthma, symptomatic
             hypotension, history of seizures

          -  Taking migraine prophylactic medication or vestibular suppressants.

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Richard Lewis</investigator_full_name>
    <investigator_title>Associate Professor, Otolaryngology and Neurology; Director, Jenks Vestibular Laboratory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vestibular Diseases</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

